Austria · Delayed Price · Currency is EUR Novo Nordisk Company Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.
It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides NovoPen 6 & NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles.
Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Country | Denmark |
| Founded | 1923 |
| Industry | Pharmaceutical Preparations |
| Employees | 78,554 |
| CEO | Maziar Doustdar |
Contact Details
Address: Novo Alle 1 Bagsvaerd, 2880 Denmark | |
| Phone | 45 44 44 88 88 |
| Website | novonordisk.com |
Stock Details
| Ticker Symbol | NNO2 |
| Exchange | Vienna Stock Exchange |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Maziar Doustdar | Chief Executive Officer |
| Karsten Knudsen | Chief Financial Officer |
| Jacob Martin Rode | Head of Investor Relations |